Shixing Zhu

ORCID: 0009-0005-5626-6574
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Antibiotics Pharmacokinetics and Efficacy
  • Antibiotic Resistance in Bacteria
  • Pneumonia and Respiratory Infections
  • Pharmaceutical and Antibiotic Environmental Impacts
  • Tuberculosis Research and Epidemiology
  • Traditional Chinese Medicine Analysis
  • Microbial infections and disease research
  • Phytochemistry and Biological Activities
  • Inflammatory mediators and NSAID effects
  • Monoclonal and Polyclonal Antibodies Research
  • Pharmacogenetics and Drug Metabolism
  • PI3K/AKT/mTOR signaling in cancer
  • Flavonoids in Medical Research
  • Chronic Lymphocytic Leukemia Research
  • Turbomachinery Performance and Optimization
  • Cytokine Signaling Pathways and Interactions
  • Antibiotic Use and Resistance
  • Combustion and flame dynamics
  • Asthma and respiratory diseases
  • Sesquiterpenes and Asteraceae Studies
  • Heat Transfer Mechanisms

Tianjin University of Technology
2025

Ocean University of China
2020-2024

China Pharmaceutical University
2018

Shanghai Institute of Materia Medica
2018

Chinese Academy of Sciences
2018

As the inlet temperature of gas turbine exceeds high limit blade materials, efficient leading edge cooling technologies are crucial for further development turbines. Therefore, this paper reviews research progress on external technology, internal and composite technology rotating cooling. It focuses impact geometric shape, arrangement, flow parameters film holes performance, influence jet hole design, configuration, crossflow, ribs efficiency, characteristics influencing factors also...

10.3390/en18030540 article EN cc-by Energies 2025-01-24

Amikacin and polymyxins as monotherapies are ineffective against multidrug-resistant Acinetobacter baumannii at the clinical dose. When polymyxins, aminoglycosides, sulbactam co-administered, combinations exhibit in vitro synergistic activities. The minimum inhibitory concentration (MIC) mutant prevention (MPC) were determined 11 5 resistant isolates of A. harboring OXA-23, respectively, order to derive fraction time over 24-h wherein free drug was within selection window (fTMSW) that above...

10.3389/fmicb.2022.1013939 article EN cc-by Frontiers in Microbiology 2022-10-20

Background The combination antimicrobial therapy consisting of amikacin, polymyxin-B, and sulbactam demonstrated in vitro synergy against multi-drug resistant Acinetobacter baumannii . Objectives objectives were to predict drug disposition extrapolate their efficacy the blood, lung, heart, muscle skin tissues using a physiologically-based pharmacokinetic (PBPK) modeling approach evaluate achievement target pharmacodynamic (PD) indices A. Methods A PBPK model was initially developed for adult...

10.3389/fmicb.2024.1435906 article EN cc-by Frontiers in Microbiology 2024-10-07

Abstract Objectives Ceftazidime/avibactam is not active against MBL-producing bacteria. Combining ceftazidime/avibactam or avibactam with aztreonam can counter the resistance of Enterobacterales. The aim this study was to evaluate whether addition could reduce close mutant selection window (MSW) in Escherichia coli and Klebsiella pneumoniae harbouring MBLs; MSW a pharmacodynamic (PD) parameter for emergent resistant mutants. Methods In vitro susceptibility 19 clinical isolates...

10.1093/jac/dkab292 article EN Journal of Antimicrobial Chemotherapy 2021-07-26

Introduction The emergence of multidrug-resistant (MDR) Acinetobacter baumannii prompts clinicians to consider treating these infections with polymyxin combination. Methods Metabolomic analysis was applied investigate the synergistic effects polymyxin-B, amikacin and sulbactam combination therapy against MDR A. harboring OXA-23 other drug resistant genes. concentrations tested were based on their clinical breakpoints: polymyxin-B (2 mg/L), (16 polymyxin-B/amikacin (2/16...

10.3389/fmicb.2023.1217270 article EN cc-by Frontiers in Microbiology 2023-06-29

This study aimed to examine specific niches and usage for the aztreonam/amoxicillin/clavulanate combination use population pharmacokinetic simulations of clinical dosing regimens predict impact this on restricting mutant selection. The in vitro susceptibility 19 New-Delhi metallo-β-lactamase (NDM)-producing isolates amoxicillin/clavulanate aztreonam alone co-administration was determined based minimum inhibitory concentration (MIC) prevention (MPC). fractions a 24-h duration that free drug...

10.3390/pharmaceutics15010251 article EN cc-by Pharmaceutics 2023-01-11

Carbapenem-resistant Acinetobacter baumannii (CRAB) is resistant to major antibiotics such as penicillin, cephalosporin, fluoroquinolone and aminoglycoside, has become a significant nosocomial pathogen. The efficacy of rifampicin colistin combination against CRAB could be dependent on the administration routes drug concentrations at site infection. objective predict disposition in biological tissues. Treatment extrapolated by assessing respective pharmacodynamic (PD) indices, well parameters...

10.1016/j.ejps.2023.106443 article EN cc-by European Journal of Pharmaceutical Sciences 2023-04-10

Empirical therapies using polymyxins combined with other antibiotics are recommended in the treatment of Acinetobacter baumannii infections. In present study, synergistic activities polymyxin-B, meropenem, and sulbactam as combination therapy were investigated metabolomic analysis. The metabolome A. was after polymyxin-B alone (2 mg/l), meropenem mg/l) alone, polymyxin-B/meropenem at their clinical breakpoints, triple-antibiotic 4 mg/l sulbactam. significantly changed metabolite levels...

10.3389/fmicb.2022.1013934 article EN cc-by Frontiers in Microbiology 2022-09-23

The objective of this study was to evaluate whether combinations sulbactam, meropenem, and polymyxin-B could reduce or close the gap mutant selection window (MSW) individual antibiotics against Acinetobacter baumannii harboring OXA-23. MICs three antimicrobials used alone in combination (meropenem/polymyxin-B meropenem/polymyxin-B/sulbactam) were obtained 11 clinical isolates prevention concentrations determined 4 isolates. All resistant meropenem polymyxin-B. Combining with without...

10.3389/fmicb.2022.1024702 article EN cc-by Frontiers in Microbiology 2022-11-22

A novel dual PI3K α/δ inhibitor, TQ-B3525, has been developed for the targeted treatment of lymphoma and solid tumors. TQ-B3525 is primarily metabolized by CYP3A4 FOM3, while also serving as a substrate P-glycoprotein transporter. The aim this study was to anticipate drug-drug interaction (DDI) its two metabolites with enzyme potent inducer (rifampicin) CYP3A4/P-gp inhibitor (itraconazole) utilizing physiologically based pharmacokinetic (PBPK) modeling approach. Clinical data from healthy...

10.1002/jcph.6111 article EN The Journal of Clinical Pharmacology 2024-08-06

Background: Apigenin, a natural plant flavone, has been shown to possess variety of biological properties. Objective: In this report, highly selective and sensitive LC-MS/MS method was developed validated for the determination apigenin in rat plasma. Methods: Analysts were separated on HSS T3 column (1.8 μm 2.1×100 mm) using acetonitrile 0.1% formic acid 2mM ammonium acetate buffer at supply rate 0.200 mL/min as eluent gradient model. Results: Plasma samples treated by protein precipitation...

10.2174/1389201021666200807113144 article EN Current Pharmaceutical Biotechnology 2020-08-08

Riemerella anatipestifer can cause septicemia and death in ducks geese, leading to significant economic losses animal farms. The emergence of resistance R. commonly used antibiotics increases the difficulty treating infection. aim this study was evaluate utility antibiotic combination restrict mutant selection multidrug-resistant (MDR) isolates. Pharmacokinetics florfenicol chlortetracycline Pekin were evaluated using both noncompartmental analysis population pharmacokinetic models. areas...

10.1089/mdr.2022.0008 article EN Microbial Drug Resistance 2022-06-20
Coming Soon ...